Investor Brand Network Press Releases & Markets News

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related...

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced the launch of Evolve(TM) Mouse. Evolve Mouse utilizes a breakthrough fertility solution to control mouse infestations. It is designated as...

SOBRsafe (NASDAQ: SOBR), a provider of next-generation, transdermal alcohol-detection solutions, continues to strengthen its position as it announces new contracts. The company recently signed a hardware/software agreement with a three-facility...

Electronic-monitoring (“EM”) security solutions developer SuperCom (NASDAQ: SPCB) has seen its revenues and gross margin grow dramatically as it serves a worldwide market for court-administered security needs and other identity technology concerns.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has partnered with Pritchard EV, a national leader in the adoption of EVs with commercial fleets and Mullen’s recently announced dealer partner, and Mobile Road...

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the launch of the fast-anneal feature, which is available on all...

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions, today announced that it will provide a business update and release its financial results for the first quarter of 2024 following the close of the...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is...

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101, an IV formulation of suramin. This...

Clene (NASDAQ: CLNN), along with its subsidies, “Clene”, and its wholly owned subsidiary Clene Nanomedicine, Inc., a pioneering clinical-stage biopharmaceutical firm dedicated to enhancing mitochondrial health and safeguarding neuronal function to...